TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8566638
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine 0.02 mg/kg (maximum 0.4 mg)
Study: 8566638
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine with meperidine
Study: 19552750
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care from a clinical pharmacist
Study: 22683276
Drug: 0.1% topical
Normalized name: Halog 0.1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% topical clonidine gel applied 3 times a day for 12 weeks
Study: 20404228
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive fractional radiofrequency (FRF) treatment
Study: 11599643
Drug: Fluoxetine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine maintenance treatment during a 62-week study
Study: 22695403
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (CONTROL)
Study: 17409767
Drug: High dialysate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dialysate calcium (HdCa) concentration of 1.75 mmol/l
Study: 17409767
Drug: Low dialysate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dialysate calcium (LdCa) concentration of 1.25 mmol/l
Study: 11779668
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg or 2 mg of oral naloxone, three times daily
Study: 9690726
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 3 mg/60 mL enema (BDP)
Study: 9690726
Drug: Prednisolone sodium
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone sodium phosphate 30 mg/60 mL enema (PP)
Study: 7916398
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Enteral feeding and Total parenteral nutrition)
Study: 29938557
Drug: Schema-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema-focused cognitive group therapy (11 sessions)
Study: 29938557
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control group (no immediate treatment)
Study: 23704912
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant therapy
Study: 10702883
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg cilostazol suspension
Study: 10702883
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg cilostazol tablet
Study: 10702883
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg cilostazol ethanolic solution
Study: 10702883
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat meal with 100 mg cilostazol
Study: 16629348
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 to 40 mg daily)
Study: 8726790
Drug: Maprotiline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (50 to 150 mg daily)
Study: 7067470
Drug: Stepped Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped Care (SC) treatment with extensive efforts to reduce barriers to care
Study: 7067470
Drug: Educational level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational level as a predictor of drug adherence
Study: 30314417
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral treatment
Study: 26544859
Drug: Virtual walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Virtual walking treatment
Study: 24569459
Drug: KRN23 (0.003-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRN23 (0.003-0.3 mg/kg i.v. or 0.1-1 mg/kg s.c.)
Study: 19046855
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 2.5 mg
Study: 19046855
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 5.0 mg
Study: 19046855
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 2.5 mg
Study: 19046855
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (both doses)
Study: 14720531
Drug: Amiodarone 400mg
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone 400mg BD for 2 weeks prior to DCCV and 200mg daily for 8 weeks followed by placebo for 44 weeks
Study: 14720531
Drug: Amiodarone 400mg
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone 400mg BD for 2 weeks then 200mg daily for 52 weeks
Study: 28242632
Drug: Eribulin 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin 1.4 mg/m2 intravenously on days 1 and 8
Study: 28242632
Drug: Dacarbazine 850,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine 850, 1,000, or 1,200 mg/m2 intravenously on day 1 of a 21-day cycle
Study: 19186315
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg (adjustable to 25 mg or 100 mg based on patient response)
Study: 16760504
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (500-1,500 microg/day) plus oral iron
Study: 15526012
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron alone
Study: 14985229
Drug: Fat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat (50 g/m² body surface)
Study: 14985229
Drug: Glucose (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (37.5 g/m²)
Study: 8499958
Drug: Systen (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systen (3.2 mg micronized 17 beta-estradiol transdermal patch)
Study: 8499958
Drug: Estraderm (older
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estraderm (older transdermal therapeutic system)
Study: 23458232
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (Control)
Study: 25248648
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine (8 ml h(‐1))
Study: 25248648
Drug: 0.4% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% ropivacaine (2 ml h(‐1))
Study: 21244474
Drug: Pitavastatin 2
Normalized name: PITAVASTATIN 2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 mg
Study: 7423602
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of ascorbic acid
Study: 9232342
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of ascorbic acid
Study: 9232342
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of ascorbic acid
Study: 8489978
Drug: Intravenous droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous droperidol (2.5 mg)
Study: 3501274
Drug: rIFN-alpha (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-alpha (5.5 megaunits/m2 body surface daily for 21 days, then twice a week for six months)
Study: 23131287
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (multienzyme tablets and mosapride dispersible tablets)
Study: 23131287
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine symptomatic treatment)
Study: 17993948
Drug: Various therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various therapies to maintain hemodynamic stability for organ donation
Study: 8548117
Drug: Maintaining sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintaining sinus rhythm through chronic administration of antiarrhythmic agents
Study: 7872185
Drug: Enoxaparin 60
Normalized name: enoxaparin 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 60 mg
Study: 1963015
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 5000 IU tds
Study: 7221357
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g of bacampicillin plus 1.0 g of probenecid
Study: 7221357
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g of bacampicillin plus 1.0 g of probenecid
Study: 7221357
Drug: 3.5 g
Normalized name: Calcium 760 MG/3.5 GM Oral Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g of ampicillin plus 1.0 g of probenecid
Study: 28925969
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg of body mass)
Study: 31331240
Drug: Standardized protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized protocol for postoperative care (4- to 6-day intubation, determined choice, dosage, and duration of sedating medications)
Study: 30012355
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral cholecalciferol (100,000 IU vitamin D3 at baseline and week 2)
Study: 22687487
Drug: Escitalopram monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram monotherapy plus placebo
Study: 22687487
Drug: Combination treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatments (bupropion SR + escitalopram or venlafaxine XR + mirtazapine)
Study: 30113928
Drug: SSRI monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI monotherapy
Study: 19625712
Drug: Standard-dose peginterferon
Normalized name: PEGINTERFERON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose peginterferon alfa‐2b (1.5 microg/kg/week) + ribavirin (800-1400 mg/day)
Study: 19625712
Drug: Low-dose peginterferon
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose peginterferon alfa‐2b (1.0 microg/kg/week) + ribavirin (800-1400 mg/day)
Study: 19625712
Drug: Peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa‐2a (180 microg/week) + ribavirin (1000-1200 mg/day)
Study: 19625712
Drug: Standard-dose peginterferon
Normalized name: PEGINTERFERON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose peginterferon alfa‐2b
Study: 19625712
Drug: Low-dose peginterferon
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose peginterferon alfa‐2b
Study: 19625712
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with undetectable HCV RNA levels at treatment weeks 4 and 12
Study: 17452491
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injection with 4 sessions of occupational therapy over 4 weeks
Study: 25808577
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy alone
Study: 15157685
Drug: Tramadol/Acetaminophen (APAP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/Acetaminophen (APAP) 75 mg/650 mg
Study: 11593710
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of droperidol 10 mg in 48 hours
Study: 11593710
Drug: Bolus doses
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus doses of droperidol 2.5 mg
Study: 9689301
Drug: Ammonium solution
Normalized name: ammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ammonium solution
Study: 8607936
Drug: IVIg 500
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg 500 mg/kg/month
Study: 28137517
Drug: Turkish classical
Normalized name: Turkish Licorice Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turkish classical music therapy for 30 minutes daily for 7 days (5 days before and 2 days after labor)
Study: 28137517
Drug: Turkish classical
Normalized name: Turkish Licorice Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turkish classical music therapy
Study: 28137517
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care and 30 minutes of bed rest daily
Study: 21632816
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Conventional insulin therapy - CIT)
Study: 20137621
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) 5 mg/kg body weight at 0, 2, and 6 weeks, followed by maintenance therapy every 8 weeks.
Study: 11242725
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic gel (20% benzocaine)
Study: 9133513
Drug: Angina-guided drug
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angina-guided drug therapy
Study: 9133513
Drug: Ischemia-guided drug
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ischemia-guided drug therapy
Study: 7595182
Drug: gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil 1200 mg day‐1
Study: 156916
Drug: Fenoterol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.5 mg, inhalation)
Study: 156916
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (0.25 mg, inhalation)
Study: 156916
Drug: Theophylline (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (240 mg, intravenous)
Study: 156916
Drug: Disodium cromoglicicum
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disodium cromoglicicum (20 mg, before tests)
Study: 21842428
Drug: DepoFoam bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoFoam bupivacaine 120 mg
Study: 17804986
Drug: Nortriptyline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline plus lithium (continuation pharmacotherapy)
Study: 11517739
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to tumor necrosis factor-alpha (anti-TNF-a)
Study: 11517739
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to interferon-gamma (anti-INF-g)
Study: 8866937
Drug: L-threo-3,4-dihydroxyphenylserine (L-DOPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 100 mg
Study: 2894232
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg once daily
Study: 26506070
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg oxandrolone orally twice daily for 24 months
Study: 22067612
Drug: Yoghurts containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoghurts containing microencapsulated L. reuteri NCIMB 30242
Study: 18629529
Drug: E (3)
Normalized name: Estrone (3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E (3) - Epidural infusion initiated 3 min after spinal induction
Study: 18629529
Drug: E (30)
Normalized name: ascorbic acid 120 MG / calcium carbonate 200 MG / cholecalciferol 0.41 MG / choline bitartrate 55 MG / ferrous fumarate 27 MG / folic acid 1 MG / niacin 20 MG / potassium iodide 0.15 MG / pyridoxine HCl 50 MG / riboflavin 3 MG / thiamine mononitrate 3 MG / vitamin B 12 8 MCG / vitamin E 0.03 MG / zinc oxide 15 MG Delayed Release Oral Tablet (30) / docosahexaenoic acid 250 MG / eicosapentaenoic acid 0.625 MG Oral Capsule (30) Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: E (30) - Epidural infusion initiated 30 min after spinal induction
Study: 18629529
Drug: E (60)
Normalized name: caffeine 65 MG / riboflavin 6.25 MG / thiamine 25 MG / vitamin B12 125 MCG / vitamin B6 25 MG Oral Capsule (60) / ibuprofen 400 MG Oral Tablet (60) Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: E (60) - Epidural infusion initiated 60 min after spinal induction
Study: 18629529
Drug: E (90)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E (90) - Epidural infusion initiated 90 min after spinal induction
Study: 15232677
Drug: Steroid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid regimen (prednisone for 4 months)
Study: 26036529
Drug: Steroid-free regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free regimen
Study: 15232677
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (steroid-free and steroids)
Study: 12190655
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone (220 micro g twice daily)
Study: 7796709
Drug: Fluconazole suspension
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole suspension (100 mg)
Study: 7796709
Drug: Fluconazole capsule
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole capsule (100 mg)
Study: 2209876
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized estradiol (E2), 2 mg
Study: 2209876
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (Es), 5 mg
Study: 19023897
Drug: IVRS administration
Normalized name: Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVRS administration of SIBDQ
Study: 19023897
Drug: IVRS administration
Normalized name: Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVRS administration of SIBDQ in active CD
Study: 19023897
Drug: IVRS administration
Normalized name: Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVRS administration of SIBDQ in active UC
Study: 19023897
Drug: IVRS administration
Normalized name: Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVRS administration of SIBDQ (first vs second administration)
Study: 11403532
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs), specifically esomeprazole at 40 mg
Study: 11403532
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of proton pump inhibitors
Study: 8146105
Drug: 414 mg
Normalized name: chloral hydrate 414 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 414 mg nitrate + nitrite and 23 mg vitamin C
Study: 8146105
Drug: 412 mg
Normalized name: calcium carbonate 412 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 412 mg nitrate + nitrite and 177 mg vitamin C
Study: 8146105
Drug: 23 mg
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 mg nitrate + nitrite and 39 mg vitamin C
Study: 8146105
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg nitrate + nitrite and 193 mg vitamin C
Study: 30336390
Drug: Cannabis use
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis use 12x/month or more during treatment
Study: 28699427
Drug: Treatment to
Normalized name: Lice Treatment Topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment to reinstate euthyroidism
Study: 15698513
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) co-therapy for 6 months
Study: 15698513
Drug: Chronic COX-2
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic COX-2 therapy
Study: 15698513
Drug: Chronic NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic NSAID therapy
Study: 11999607
Drug: Inhalation anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthesia with desflurane or sevoflurane
Study: 11999607
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered by target controlled infusion
Study: 10155331
Drug: Epoetin 6000U
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin 6000U weekly for 2 months
Study: 10155331
Drug: Epoetin 9000U
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin 9000U weekly for 2 months
Study: 10155331
Drug: Epoetin 12000U
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin 12000U weekly for 2 months
Study: 10155331
Drug: Sensitivity analysis
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitivity analysis on drug administration cost
Study: 2664718
Drug: Other relaxation
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other relaxation treatments
Study: 195709
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with chemotherapy